United Therapeutics (STU:UTH) Inventories, Finished Goods : €59 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is United Therapeutics Inventories, Finished Goods?

United Therapeutics's quarterly finished goods increased from Sep. 2023 (€45 Mil) to Dec. 2023 (€51 Mil) and increased from Dec. 2023 (€51 Mil) to Mar. 2024 (€59 Mil).

United Therapeutics's annual finished goods increased from Dec. 2021 (€39 Mil) to Dec. 2022 (€48 Mil) and increased from Dec. 2022 (€48 Mil) to Dec. 2023 (€51 Mil).

United Therapeutics Inventories, Finished Goods Historical Data

The historical data trend for United Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Inventories, Finished Goods Chart

United Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

38.88

31.73

39.21

47.86

51.08

United Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															48.85	44.95	44.88	51.08	58.70

United Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

United Therapeutics (STU:UTH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (STU:UTH) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

UTHR:USA

Address

1040 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics (STU:UTH) Headlines

No Headlines